NEW YORK (GenomeWeb News) – Leukocare and Trillium Diagnostics today announced a deal to develop and market Leukocare's method for detecting inflammatory activity using circulating cell-free DNA.

Trillium will use the method to develop a commercial assay for diagnosing sepsis, they said. Under the terms of the deal, Leukocare grants Trillium an exclusive, royalty-bearing license to its patent covering the technology and know-how for measuring the quantity of cf-DNA to develop a commercial in vitro diagnostic assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.